Document Detail

Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.
MedLine Citation:
PMID:  19457692     Owner:  NLM     Status:  MEDLINE    
A 72-year-old male with a 4-year history of TNFalpha antagonist therapy (infliximab and etanercept) for ankylosing spondylitis was diagnosed with breast cancer. He had a family history of breast cancer. The low incidence and considerable severity of breast cancer in males, genetic risk factors, and potential role for TNFalpha antagonist therapy are discussed.
Laila El Mansouri; Tifenn Couchouron; Guillaume Le Roux; Catherine Dugast; Françoise Burtin; Jean-David Albert; Aleth Perdriger; Najia Hajjaj Hassouni; Gérard Chalès
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-05-19
Journal Detail:
Title:  Joint, bone, spine : revue du rhumatisme     Volume:  76     ISSN:  1778-7254     ISO Abbreviation:  Joint Bone Spine     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-14     Completed Date:  2009-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100938016     Medline TA:  Joint Bone Spine     Country:  France    
Other Details:
Languages:  eng     Pagination:  421-3     Citation Subset:  IM    
Service de Rhumatologie, CHU Rennes, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Breast Neoplasms, Male / diagnosis*,  genetics,  physiopathology
Genes, BRCA2
Genetic Predisposition to Disease
Immunoglobulin G / adverse effects,  therapeutic use*
Receptors, Tumor Necrosis Factor / therapeutic use*
Risk Factors
Spondylitis, Ankylosing / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  physiology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of re...
Next Document:  Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of rec...